FORM PTO-1449 (Modified)

poreved for use through 10/31/2002

US DEPARTMENT OF COMMERCE

US Patent and Trademark Office

Application No. Docket No. 50623.362 10/751,043

INPORMATION DISCLOSURE CITATION in an Application

Applicant

Syed F.A. Hossainy et al.

(Use several sheets if necessary)

Filing Date

Group Art Unit

January 2, 2004 1616 **U.S. PATENT DOCUMENTS** Subclass Filing Date if Ref. No Date of Name Class Examiner **Document** Initial Patent Appropriate Number /KG/ 5/11/82 428 36 Joh Α1 4,329,383 A2 3/29/88 Palmaz 128 343 4,733,665 A3 4,800,882 1/31/89 Gianturco 128 343 A4 11/21/89 Casey et al. 424 468 4,882,168 A5. 12/12/89 Wiktor 128 343 4,886,062 7/17/90 Okada et al. 600 36 Α6 4,941,870 **A7** 4,977,901 12/18/90 Ofstead 128 772 A8 5,112,457 5/12/92 Marchant 204 165 Α9 5,165,919 11/24/92 Sasaki et al. 424 488 5,272,012 12/21/93 423.1 A10 Opolski 428 3/8/94 423 A11 5,292,516 Viegas et al. 424 A12 3/29/94 486 5,298,260 Viegas et al. 424 A13 5,300,295 4/5/94 Viegas et al. 424 427 A14 5,306,501 4/26/94 Viegas et al. 424 423 7/12/94 604 101 A15 5,328,471 Slepian A16 5,330,768 7/19/94 Park et al. 424 501 A17 5,380,299 1/10/95 Fearnot et al. 604 265 5/23/95 Endo et al. 424 486 A18 5,417,981 9/5/95 424 426 A19 5,447,724 Helmus et al. A20 5,455,040 10/3/95 Marchant 424 426 10/31/95 A21 5,462,990 Hubbell et al. 525 54.1 A22 5,464,650 11/7/95 2.30 Berg et al. 427 A23 5,569,463 10/29/96 Helmus et al. 424 426 A24 5.578.073 11/26/96 Haimovich et al. 623 1 A25 5,605,696 2/25/97 Eury et al. 424 423 /KG/ A26 5,609,629 3/11/97 Fearnot et al. 623 1

/KG/	A27	5,624,411	4/29/97	Tuch	604	265	
1	A28	5,628,730	5/13/97	Shapland et al.	604	21	
	A29	5,649,977	7/22/97	Campbell	623	1	
	A30	5,658,995	8/19/97	Kohn et al.	525	432	
	A31	5,667,767	9/16/97	Greff et al.	424	9.411	
	A32	5,670,558	9/23/97	Onishi et al.	523	112	
	A33	5,679,400	10/21/97	Tuch	427	2.14	
	A34	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A35	5,702,754	12/30/97	Zhong	427	2.12	
	A36	5,716,981	2/10/98	Hunter et al.	514	449	
	A37	5,735,897	4/7/98	Buirge	623	12	
	A38	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A39	5,776,184	7/7/98	Tuch	623	. 1	
	A40	5,788,979	8/4/98	Alt et al.	424	426	
	A41	5,800,392	9/1/98	Racchini	604	96	
	A42	5,820,917	10/13/98	Tuch	427	2.1	
	A43	5,824,048	10/20/98	Tuch	623	1	
	A44	5,824,049	10/20/98	Ragheb et al.	623	1	
	A45	5,830,178	11/3/98	Jones et al.	604	49	
	A46	5,837,008	11/17/98	Berg et al.	623	. 1	
	A47	5,837,313	11/17/98	Ding et al.	427	2.21	
	A48	5,851,508	12/22/98	Greff et al.	424	9.411	
	A49	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A50	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A51	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A52	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A53	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A54	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A55	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/9
	A56	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
V	A57	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
/KG/	A58	5,980,928	11/9/99	Terry	424	427	7/29/97

/KG/	A59	5,980,972	11/9/99	Ding	427	2.24	9/22/97
1	A60	5,997,517 12/7/99		Whitbourne	604	265	1/27/97
	A61	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A62	6,015,541	1/18/00	3/7/00 Lee et al.		1.25	11/3/97
	A63	6,033,582	3/7/00			37	1/16/98
	A64	6,042,875	3/28/00			2.24	3/2/99
	A65	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A66	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A67	6,056,993	5/2/00	Leidner et al. DiMaio et al. Kabanov et al. Hostettler et al.		2.25	4/17/98
	A68	6,060,451	5/9/00			13 781 423.3	3/20/95 8/16/96
	A69	6,060,518	5/9/00				
	A70	6,080,488	6/27/00				3/24/98
	A71	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A72	A72 6,099,562		Ding et al.	623	1.46	12/22/97
	A73	A73 6,110,188 8/29/00 Narciso, Jr. A74 6,110,483 8/29/00 Whitbourne et al.		606	153	3/9/98	
	A74			Whitbourne et al.	424	423	6/23/97
	A75	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A76	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A77	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A78	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A79	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A80	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A81	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A82	6,203,551	3/20/01	Wu	606	108	10/4/99
	A83	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A84	6,240,616	6/5/01	Yan	29	527.2	4/15/97
1	A85	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A86	6,251,136	6/26/01	6/26/01 Guruwaiya et al.		1.46	12/8/99
	A87	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
$\overline{\mathbf{V}}$	A88	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
/KG/	A89	6,283,947	9/4/01	Mirzaee	604	264	7/13/99

/KG/	A90	6,283,949	9/4/01	Roorda	604	288.02	12/27/99	
1	A91	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00	
	A92	6,287,628	9/11/01	Hossainy et al.		2.3	9/3/99	
	A93	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99	
	A94	6,306,176	10/23/01	10/23/01 Whitbourne		23.59	9/21/99	
	A95	6,331,313	12/18/01	Wong et al.	424	427	10/22/99	
	A96	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98	
	A97	6,346,110	2/12/02	Wu	606	108	1/3/01	
	A98	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98	
	A99	A99 6,379,381 4/30/02		Hossainy et al.	623	1.42	9/3/99	
	A100	6,395,326	5/28/02	Castro et al.	427 623	2.24 1.15	5/31/00 2/3/99	
	A101	6,419,692	7/16/02	Yang et al.				
	A102	6,451,373	9/17/02	Hossainy et al.		2.25	8/4/00	
	A103	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99	
	A104	6,503,556	1/7/03	1/7/03 Harish et al.		2.24	12/28/00	
	A105	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00	
	A106	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00	
	A107	6,527,801	3/4/03	Dutta	623	1.46	4/13/00	
	A108	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01	
	A109	6,540,776	4/1/03	Sanders Millare et al. 623	1.15	12/28/00		
	A110	6,544,223	4/8/03	Kokish		103.01	1/5/01	
	A111	6,544,543	4/8/03	Mandrusov et al.	Mandrusov et al. 424	422	12/27/00	
	A112	6,544,582	4/8/03		427	2.24	1/5/01	
	A113	6,555,157	4/29/03		427	2.24	7/25/00	
	A114	A114 6,558,733 5/6/03 Hossainy et al.		427	2.24	10/26/00		
	A115	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01	
	A116	6,572,644	6/3/03	Moein	623	1.11	6/27/01	
V	A117	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00	
/KG/	A118	6,585,926	7/1/03	Mirzaee	264	400	8/31/00	

/KG/	A119	6,605,154	8/12/03	Villareal	118	500	5/31/01	
		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCUM	MENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate	
/KG/	A120	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00	
	A121	2001/0037145	11/1/01	Guruwaiya et al.	623.	1.15	6/21	/01
<u> </u>	A122	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
	A123	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A124	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	/01
V	A125	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02	
/KG/	A126	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS	,			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
/KG/	B1	EP 0 301 856	2/1/89	EPO				
1_	B2	EP 0 514 406	11/25/92	EPO				
	В3	EP 0 604 022	6/29/94	EPO				
	B4	EP 0 623 354	11/9/94	EPO				
	B5	EP 0 665 023	8/2/95	EPO				
	B6	EP 0 701 802	3/20/96	EPO				
	В7	EP 0 716 836	6/19/96	EPO				
	В8	EP 0 809 999	12/3/97	EPO				
	В9	EP 0 832 655	4/1/98	EPO				
	B10	EP 0 850 651	7/1/98	EPO				
·	B11	EP 0 879 595	11/25/98	EPO				
	B12	EP 0 910 584	4/28/99	EPO				
	B13	EP 0 923 953 .	6/23/99	EPO				
	B14	EP 0 953 320	11/3/99	EPO				
	B15	EP 0 970 711	1/12/00	EPO				
	B16	EP 0 982 041	3/1/00	EPO				-
	B17	EP 1 273 314	1/8/03	EPO				
	B18	2001-190687	7/17/01	Japan (Abstract)			Х	
V	B19	WO 91/12846	9/5/91	WIPO				
/KG/	B20	WO 95/10989	4/27/95	WIPO				

/KG/	B21	WO 96/40174	12/19/96	WIPO				
1	B22	WO 97/10011	3/20/97	WIPO				
	B23	WO 97/45105	12/4/97	WIPO				
	B24	WO 97/46590	12/11/97	WIPO				
	B25	WO 98/17331	4/30/98	WIPO				
	B26	WO 98/36784	8/27/98	WIPO				
	B27	WO 99/01118	1/14/99	· WIPO				
	B28	WO 99/38546	8/5/99	WIPO				
	B29	WO 99/63981	12/16/99	WIPO				
	B30	WO 00/02599	1/20/00	WIPO				
	B31	WO 00/12147	3/9/00	WIPO				
	B32	WO 00/18446	4/6/00	WIPO				
	B33	WO 00/64506	11/2/00	WIPO				
	B34	WO 01/01890	1/11/01	WIPO				
	B35	WO 01/15751	3/8/01	WIPO				
	B36	WO 01/17577	3/15/01	WIPO				
	B37	WO 01/45763	6/28/01	WIPO				
	B38	WO 01/49338	7/12/01	WIPO				
	B39	WO 01/74414	10/11/01	WIPO				
	B40	WO 02/03890	1/17/02	WIPO				
	B41	WO 02/026162	4/4/02	WIPO				
	B42	WO 02/34311	5/2/02	WIPO				
	B43	WO 02/056790	7/25/02	WIPO				
	B44	WO 03/000308	1/3/03	WIPO				
	B45	WO 03/022323	3/20/03	WIPO				
1	B46	WO 03/028780	4/10/03	WIPO				
Ψ	B47	WO 03/037223	5/8/03	WIPO				
KG/	B48	WO 03/039612	5/15/03	WIPO				
		OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertinent F	Pages, etc	.)		
/KG/	C1			he Dream Stent, Clinica 710:15 (. ht?req=1061848202959, printed 8				
/KG/	C2			complications by 30%, Clinica 73 ht?req=1061847871753, printed 8			96),	

/KG/	СЗ	Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cqi/document?req=1061848017752 , printed 8/25/03 (2 pages).
	C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
	C6	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C7	Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles, Journal of Controlled Release 65:93-103 (2000).
	С9	Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	C10	Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).
	C11	Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).
	C12	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).
	C13	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).
	C14	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
	C15	Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).
	C16	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C17	Liu et al., Drug release characteristics of unimolecular polymeric micelles, Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	· C23	Ohsawa et al., Preventive Effects of an Antiellergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).
V	C24	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
/KG/	C25	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).

/KG/	C26	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:68 694 (1996).					
	C27	Shigeno, <i>Prevention of Cerebrovascula</i> Abstract 125:212307 (1996).	nr Spasm By Bosen	ntan, Novel Endothelin Receptor, Chemical			
	C28	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).					
\forall	C29	Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trend Cardiovasc. Med. 3(5):163-170 (1993).					
/KG/	C30	Yokoyama et al., Characterization of pheologymeric micelles and their design for 50:79-92 (1998).	nysical entrapment in vivo delivery to a	and chemical conjugation of adriamycin in a solid tumor, Journal of Controlled Release			
EXAMINER	/Kc	onata George/	DATE CONSIDERED	03/11/2007			
	nitial if ref		ance with MPEP § 609; Dra	w line through citation if not in conformance and not considered.			